ClinicalTrials.gg
RecruitingNCT05568719Updated Nov 17, 2026

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

A Phase 3 interventional study of Testing of hepatic AAV Vector integration in Hemophilia A and Hemophilia B, sponsored by Pfizer. Recruiting at 44 sites in 14 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Pfizer · Phase 3, Interventional, and Other

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 10 months later.
Updated Nov 17, 2026First sites in 7 new countriesSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
173
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Hemophilia A by Pfizer — 6 open to participants now, 9 under way, 6 of them phase 3. Hemophilia A · Pfizer.

Planned enrollment
5th of 32
173 · median 34
Started
2022
with 1 other
Phase 3
15 of 47
4 open now
Registered
41st of 47
by date

Among the 47 studies in Hemophilia A by Pfizer, this one is the 5th largest by planned enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2022, is one of 15 in phase 3, and was the 41st registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

6 of the 47 studies in Hemophilia A by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Hemophilia A by Pfizer, or all of them as a file.
02

Study summary

A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.

03

Conditions studied

  • Hemophilia A
  • Hemophilia B

Keywords

  • bleeding
  • adeno-associated virus based vector
  • gene therapy
  • giroctocogene fitelparvovec
  • fidanacogene elaparvovec
  • factor VIII
  • factor IX
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Only participants who received giroctocogene fitelparvovec or fidanacogene eleparvovec and were enrolled in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003) are eligible.

Exclusion criteria

Exclusion Criteria:

-None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
173 participants (estimated)

Study arms

  • Other
    Hemophilia A / giroctocogene fitelparvovec

    Participants have received treatment with giroctocogene fitelparvovec in a previous study and are not receiving any investigational product in this study

    Diagnostic Test: Testing of hepatic AAV Vector integration

  • Other
    Hemophilia B / fidanacogene elaparvovec

    Participants have received treatment with fidanacogene elaparvovec in a previous study and are not receiving any investigational product in this study

    Diagnostic Test: Testing of hepatic AAV Vector integration

Interventions

  • Diagnostic testTesting of hepatic AAV Vector integration

    Evaluation of AAV vector integration in participants for whom a sample of liver has been obtained through biopsy or surgical resection when clinically indicated

06

What researchers measure

Primary outcomes

  1. Incidence of thromboembolic events

    Time frame: Day 1 to 10 years

  2. Incidence of factor inhibitor development

    FIX inhibitor development was defined as an inhibitor titer \>= 0.6 Bethesda units per milliliter (BU/mL).

    Time frame: Day 1 to 10 years

  3. Incidence of hepatic malignancy

    Time frame: Day 1 to 10 years

  4. Incidence of liver abnormalities

    Time frame: Day 1 to 10 years

  5. Factor activity level

    Factor activity level will be reported. Factor levels may be measured using different assay methods including a one-stage assay or by chromogenic substrate assay and a second one-stage assay.

    Time frame: Day 1 to 10 years

Secondary outcomes

  1. Total ABR (treated or untreated; (excluding bleeds related to surgery)

    ABR (Annual Bleed Rate): number of bleeding episodes per year. This includes treated and untreated bleeds. The ABR or the annualized number of bleeding episodes per year, will be derived for each participant for each observation period by using the following formula: ABR = (Number of bleeds / Days in observation period) x 365.25 days/year.

    Time frame: Day 1 to 10 years

  2. Incidence of and time from vector infusion to resumption of prophylaxis

    Describe incidence of resumption of prophylaxis resumption and the time (in days) to resumption of prophylaxis after receiving vector infusion.

    Time frame: Day 1 to 10 years

  3. AIR of exogenous factor (excluding infusions related to surgery)

    The AIR or the annualized number of FIX infusions per year, will be derived for each participant for each observation period by using the following formula: AIR = (Number of FIX infusions / Days in observation period) x 365.25 days/year.

    Time frame: Day 1 to 10 years

  4. Consumption of exogenous factor (excluding infusions related to surgery)

    The annualized TFC in international units (IU) will be derived for each participant for each observation period using the following formula: Annualized TFC = (Total units of FIX infused (IU)/ Days in observation period) x 365.25 days/year

    Time frame: Day 1 to 10 years

  5. Incidence of Non-hepatic malignancy

    Time frame: Day 1 to 10 years

  6. Incidence of Auto-immune disorders

    Time frame: Day 1 to 10 years

  7. Incidence of SAEs

    An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; development of a clinical thrombotic event; development of factor inhibitor; development of a hepatic malignancy; development of drug-related elevated hepatic transaminases that fail to improve with immunosuppressive regimens; occurrence of a malignancy with reasonable possibility of being related to study drug.

    Time frame: Day 1 to 10 years

  8. All cause mortality

    All-cause mortality was defined as the death due to any cause during the course of study. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. Incidence rate of all-cause deaths was reported in this outcome measure.

    Time frame: Day 1 to 10 years

  9. EQ-5D-5L dimension and VAS scores

    The EQ-5D-5L comprises a 5-item health status measure and a visual analog rating scale/feeling thermometer. Using the 5-dimensional Health State Classification, participants are asked to respond to five questions on different aspects of their health status that assess the following: 1. Mobility 2. Self-care 3. Usual activities 4. Pain/Discomfort 5. Anxiety/Depression

    Time frame: Day 1 to 10 years

07

Study locations

38 of 44 sites recruiting
  • The Regents of the University of California||UC Davis Health
    Rancho Cordova, California 95670, United States
    Recruiting
  • UC Davis Health
    Sacramento, California 95816, United States
    Recruiting
  • UC Davis Ambulatory Care Clinic
    Sacramento, California 95817, United States
    Recruiting
  • UC Davis Hemophilia Treatment Center
    Sacramento, California 95817, United States
    Recruiting
  • UC Davis Medical Center
    Sacramento, California 95817, United States
    Recruiting
  • UCSF Outpatient Hematology Clinic
    San Francisco, California 94143, United States
    Recruiting
  • USF Health Morsani Center For Advanced Healthcare
    Tampa, Florida 33612, United States
    Recruiting
  • The University of South Florida Board of Trustees
    Tampa, Florida 33620, United States
    Recruiting
  • Innovative Hematology, Inc.
    Indianapolis, Indiana 46260, United States
    Recruiting
  • Mississippi Center For Advanced Medicine
    Madison, Mississippi 39110, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Cornell University||Joan & Sanford I. Weill Medical College
    New York, New York 10065, United States
    Recruiting
  • Weill Cornell Medical College-New York Presbyterian Hospital
    New York, New York 10065, United States
    Recruiting
  • The Childrens Hospital of Philadelphia Division of Hematology
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • The Childrens Hospital of Philadelphia Division of Hematology
    Philadelphia, Pennsylvania 19146, United States
    Recruiting
  • Washington Institute for Coagulation
    Seattle, Washington 98101, United States
    Recruiting
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
    Recruiting
  • Sydney Local Health District (RPAH Zone)
    Camperdown, New South Wales 2050, Australia
    Recruiting
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
    Recruiting
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti - HEMORIO
    Rio de Janeiro, 20211-030, Brazil
    Not yet recruiting
  • Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti- HEMORIO
    Rio de Janeiro, 20211-030, Brazil
    Not yet recruiting
  • Unity Health Toronto, St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
    Recruiting
  • Center for Applied Ethics McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
    Not yet recruiting
  • Hospices Civils de Lyon - Hopital Louis Pradel
    Bron, Rhône 69677, France
    Recruiting
  • Hôpital Universitaire Necker Enfants Malades
    Paris, 75015, France
    Recruiting
  • Universitätsklinikum Bonn
    Bonn, North Rhine-Westphalia 53127, Germany
    Recruiting
  • General Hospital of Athens Laiko
    Athens, 11527, Greece
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Nagoya University Hospital
    Nagoya, Aichi-ken 466-8560, Japan
    Recruiting
  • Sapporo Tokushukai Hospital
    Sapporo, Hokkaido 004-0041, Japan
    Recruiting
  • Saitama Medical University Hospital
    Iruma-gun, Saitama 350-0495, Japan
    Recruiting
  • Ogikubo Hospital
    Suginami-ku, Tokyo 167-0035, Japan
    Recruiting
  • King Faisal Specialist Hospital and Research Center
    Riyadh, 11211, Saudi Arabia
    Not yet recruiting
  • Kyung Hee University Hospital at Gangdong
    Seoul, 05278, South Korea
    Recruiting
  • Hospital Universitario Rio Hortega
    Valladolid, 47012, Spain
    Recruiting
  • Skåne University Hospital
    Malmö, 21428, Sweden
    Recruiting
  • Changhua Christian Hospital
    Changhua, 500, Taiwan
    Recruiting
  • Chung-Ho Memorial Hospital, Kaohsiung Medical University
    Kaohsiung City, 807, Taiwan
    Recruiting
  • Chung Shan Medical University Hospital
    Taichung, 402, Taiwan
    Recruiting
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
    Recruiting
  • National Taiwan University Hospital
    Taipei, 10041, Taiwan
    Recruiting
  • Ege Universitesi Hastanesi
    Izmir, İ̇zmir 35100, Turkey (Türkiye)
    Recruiting
  • Acibadem Adana Hospital
    Adana, 01130, Turkey (Türkiye)
    Recruiting
  • Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi
    Gaziantep, 27310, Turkey (Türkiye)
    Recruiting
  • İstanbul Üniversitesi Onkoloji Enstitüsü
    Istanbul, 34093, Turkey (Türkiye)
    Recruiting
08

References and documents

Publications

  • Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012 Apr 14;379(9824):1447-56. doi: 10.1016/S0140-6736(11)61139-2. Epub 2012 Mar 27. PubMed 22456059 ↗
  • WFH guidelines: https://www1.wfh.org/publication/files/pdf-1472.pdf
  • Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014 Nov;12(11):1935-9. doi: 10.1111/jth.12672. Epub 2014 Sep 3. No abstract available. PubMed 25059285 ↗
  • Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia. 2003 May;9 Suppl 1:19-26; discussion 26. doi: 10.1046/j.1365-2516.9.s1.12.x. PubMed 12709033 ↗
  • Lillicrap D. Extending half-life in coagulation factors: where do we stand? Thromb Res. 2008;122 Suppl 4:S2-8. doi: 10.1016/S0049-3848(08)70027-6. PubMed 18929522 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Feb 2040, 205 months after the start.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 205 months is above that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 6, 2022
StartActual
Dec 28, 2022
Primary completionEst.
Feb 25, 2040
CompletionEst.
Feb 25, 2040
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites added — first sites in France, Germany, Greece, Japan, Saudi Arabia and 2 more
All 7 countries

France, Germany, Greece, Japan, Saudi Arabia, Spain, Brazil

. 12 sites changed recruiting status (11 now recruiting, 1 now active, not recruiting)
Show 12 sites
  • UCSF Outpatient Hematology Clinic · San Francisco, United StatesNot yet recruiting→Recruiting
  • Washington Institute for Coagulation · Seattle, United StatesNot yet recruiting→Recruiting
  • Unity Health Toronto, St. Michael's Hospital · Toronto, CanadaNot yet recruiting→Recruiting
  • Kyung Hee University Hospital at Gangdong · Seoul, South KoreaNot yet recruiting→Recruiting
  • Skåne University Hospital · Malmö, SwedenNot yet recruiting→Recruiting
  • Taichung Veterans General Hospital · Taichung, TaiwanNot yet recruiting→Recruiting
  • National Taiwan University Hospital · Taipei, TaiwanNot yet recruiting→Recruiting
  • Acibadem Adana Hospital · Adana, Turkey (Türkiye)Not yet recruiting→Recruiting
  • Chung-Ho Memorial Hospital, Kaohsiung Medical University · Kaohsiung City, TaiwanNot yet recruiting→Recruiting
  • Changhua Christian Hospital · Changhua, TaiwanNot yet recruiting→Recruiting
  • General Hospital of Athens Laiko · Athens, GreeceRecruiting→Active, not recruiting
  • Chung Shan Medical University Hospital · Taichung, TaiwanNot yet recruiting→Recruiting
Show 21 added (4 Japan, 3 Taiwan, 2 Australia, 2 France, 2 Turkey (Türkiye), 2 Brazil, 1 United States, 1 Germany, 1 Greece, 1 Saudi Arabia, 1 Spain, 1 Canada)
  • Innovative Hematology, Inc. · Indianapolis, United States
  • The Alfred Hospital · Melbourne, Australia
  • Hospices Civils de Lyon - Hopital Louis Pradel · Bron, France
  • Hôpital Universitaire Necker Enfants Malades · Paris, France
  • Universitätsklinikum Bonn · Bonn, Germany
  • General Hospital of Athens Laiko · Athens, Greece
  • Nagoya University Hospital · Nagoya, Japan
  • Sapporo Tokushukai Hospital · Sapporo, Japan
  • Saitama Medical University Hospital · Iruma-gun, Japan
  • King Faisal Specialist Hospital and Research Center · Riyadh, Saudi Arabia
  • Hospital Universitario Rio Hortega · Valladolid, Spain
  • Changhua Christian Hospital · Changhua, Taiwan
  • Chung-Ho Memorial Hospital, Kaohsiung Medical University · Kaohsiung City, Taiwan
  • Chung Shan Medical University Hospital · Taichung, Taiwan
  • Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi · Gaziantep, Turkey (Türkiye)
  • İstanbul Üniversitesi Onkoloji Enstitüsü · Istanbul, Turkey (Türkiye)
  • Royal Brisbane and Women's Hospital · Herston, Australia
  • Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti - HEMORIO · Rio de Janeiro, Brazil
  • Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti- HEMORIO · Rio de Janeiro, Brazil
  • Center for Applied Ethics McGill University Health Centre · Montreal, Canada
  • Ogikubo Hospital · Suginami-ku, Japan
across 4 updates, Oct 2, 2026 – Nov 17, 2026
Show all 4 updates
  1. Nov 17, 2026
    5 sites added — first site in Brazil. 2 sites changed recruiting status (1 now active, not recruiting, 1 now recruiting)
    Show 2 sites
    • General Hospital of Athens Laiko · Athens, GreeceRecruiting→Active, not recruiting
    • Chung Shan Medical University Hospital · Taichung, TaiwanNot yet recruiting→Recruiting
    Show 5 added (2 Brazil, 1 Australia, 1 Canada, 1 Japan)
    • Royal Brisbane and Women's Hospital · Herston, Australia
    • Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti - HEMORIO · Rio de Janeiro, Brazil
    • Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti- HEMORIO · Rio de Janeiro, Brazil
    • Center for Applied Ethics McGill University Health Centre · Montreal, Canada
    • Ogikubo Hospital · Suginami-ku, Japan
    + 1 other change: verification date
  2. Oct 7, 2026
    Changhua Christian Hospital is now Recruiting
  3. Oct 6, 2026
    Chung-Ho Memorial Hospital, Kaohsiung Medical University is now Recruiting
    + 1 other change: verification date
  4. Oct 2, 2026
    16 sites added — first sites in France, Germany, Greece, Japan, Saudi Arabia and 1 more
    All 6 countries

    France, Germany, Greece, Japan, Saudi Arabia, Spain

    . 8 sites changed recruiting status (8 now recruiting)
    Show 8 sites
    • UCSF Outpatient Hematology Clinic · San Francisco, United StatesNot yet recruiting→Recruiting
    • Washington Institute for Coagulation · Seattle, United StatesNot yet recruiting→Recruiting
    • Unity Health Toronto, St. Michael's Hospital · Toronto, CanadaNot yet recruiting→Recruiting
    • Kyung Hee University Hospital at Gangdong · Seoul, South KoreaNot yet recruiting→Recruiting
    • Skåne University Hospital · Malmö, SwedenNot yet recruiting→Recruiting
    • Taichung Veterans General Hospital · Taichung, TaiwanNot yet recruiting→Recruiting
    • National Taiwan University Hospital · Taipei, TaiwanNot yet recruiting→Recruiting
    • Acibadem Adana Hospital · Adana, Turkey (Türkiye)Not yet recruiting→Recruiting
    Show 16 added (3 Japan, 3 Taiwan, 2 France, 2 Turkey (Türkiye), 1 United States, 1 Australia, 1 Germany, 1 Greece, 1 Saudi Arabia, 1 Spain)
    • Innovative Hematology, Inc. · Indianapolis, United States
    • The Alfred Hospital · Melbourne, Australia
    • Hospices Civils de Lyon - Hopital Louis Pradel · Bron, France
    • Hôpital Universitaire Necker Enfants Malades · Paris, France
    • Universitätsklinikum Bonn · Bonn, Germany
    • General Hospital of Athens Laiko · Athens, Greece
    • Nagoya University Hospital · Nagoya, Japan
    • Sapporo Tokushukai Hospital · Sapporo, Japan
    • Saitama Medical University Hospital · Iruma-gun, Japan
    • King Faisal Specialist Hospital and Research Center · Riyadh, Saudi Arabia
    • Hospital Universitario Rio Hortega · Valladolid, Spain
    • Changhua Christian Hospital · Changhua, Taiwan
    • Chung-Ho Memorial Hospital, Kaohsiung Medical University · Kaohsiung City, Taiwan
    • Chung Shan Medical University Hospital · Taichung, Taiwan
    • Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi · Gaziantep, Turkey (Türkiye)
    • İstanbul Üniversitesi Onkoloji Enstitüsü · Istanbul, Turkey (Türkiye)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05568719
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 6, 2022
Start date
Dec 28, 2022
Primary completion
Feb 25, 2040 (estimated)
Completion
Feb 25, 2040 (estimated)
Last update
Nov 17, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion